PA
KNSA icon

Parallel Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Parallel Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57K Buy
892
+357
+67% +$18.5K ﹤0.01% 2055
2026
Q1 		$25.8K Hold
535
– – ﹤0.01% 2362
2025
Q4 		$22.1K Sell
535
-1
-0.2% -$40 ﹤0.01% 2233
2025
Q3 		$20.8K Buy
536
+9
+2% +$292 ﹤0.01% 2225
2025
Q2 		$14.6K Buy
527
+111
+27% +$2.83K ﹤0.01% 2333
2025
Q1 		$9.24K Hold
416
– – ﹤0.01% 2463
2024
Q4 		$8.23K Sell
416
-105
-20% -$2.4K ﹤0.01% 2476
2024
Q3 		$13K Hold
521
– – ﹤0.01% 2304
2024
Q2 		$9.73K Buy
521
+3
+0.6% +$56 ﹤0.01% 2330
2024
Q1 		$10.2K Hold
518
– – ﹤0.01% 2305
2023
Q4 		$9.09K Sell
518
-161
-24% -$2.65K ﹤0.01% 2323
2023
Q3 		$11.8K Buy
679
+42
+7% +$708 ﹤0.01% 2109
2023
Q2 		$8.97K Buy
637
+446
+234% +$5.97K ﹤0.01% 2216
2023
Q1 		$2.06K Buy
+191
New +$2.52K ﹤0.01% 2766
2022
Q1 		– Sell
-24
Closed – – 3120
2021
Q4 		$0 Buy
+24
New +$295 ﹤0.01% 3190

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Parallel Advisors's KNSA Position: Q2 2026 in Review

Parallel Advisors increased its Kiniksa Pharmaceuticals (KNSA) stake by 67% in Q2 2026, buying an estimated $18.5K and bringing the position to 892 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #2055.

Parallel Advisors first reported a position in KNSA in Q4 2021 and has held it in 15 quarters since. 191 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Parallel Advisors held 892 shares of Kiniksa Pharmaceuticals worth $57K as of Q2 2026.
  • Parallel Advisors bought 357 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $18.5K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2055 holding.
  • Parallel Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • 191 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.